Brandon Esther F A, Raap Christiaan D, Meijerman Irma, Beijnen Jos H, Schellens Jan H M
Division of Drug Toxicology, Department of Biomedical Analysis, Faculty of Pharmaceutical Sciences, Utrecht University, The Netherlands.
Toxicol Appl Pharmacol. 2003 Jun 15;189(3):233-46. doi: 10.1016/s0041-008x(03)00128-5.
The liver is the predominant organ in which biotransformation of foreign compounds takes place, although other organs may also be involved in drug biotransformation. Ideally, an in vitro model for drug biotransformation should accurately resemble biotransformation in vivo in the liver. Several in vitro human liver models have been developed in the past few decades, including supersomes, microsomes, cytosol, S9 fraction, cell lines, transgenic cell lines, primary hepatocytes, liver slices, and perfused liver. A general advantage of these models is a reduced complexity of the study system. On the other hand, there are several more or less serious specific drawbacks for each model, which prevents their widespread use and acceptance by the regulatory authorities as an alternative for in vivo screening. This review describes the practical aspects of selected in vitro human liver models with comparisons between the methods.
肝脏是外源化合物进行生物转化的主要器官,尽管其他器官也可能参与药物生物转化。理想情况下,药物生物转化的体外模型应准确模拟肝脏中的体内生物转化。在过去几十年中,已经开发了几种体外人肝模型,包括超微粒体、微粒体、胞质溶胶、S9组分、细胞系、转基因细胞系、原代肝细胞、肝切片和灌注肝脏。这些模型的一个普遍优点是研究系统的复杂性降低。另一方面,每个模型都存在或多或少严重的特定缺点,这阻碍了它们作为体内筛选替代方法的广泛使用和监管机构的认可。本综述描述了所选体外人肝模型的实际情况,并对这些方法进行了比较。